| ESALF Stock | | | USD 30.00 2.24 6.95% |
Insider
Yosuke Akita is Chief VP of Eisai Co
| Age | 58 |
| Phone | 81 3 3817 3700 |
| Web | https://www.eisai.co.jp |
Eisai Management Efficiency
Eisai's management efficiency ratios could be used to measure how well Eisai manages its routine affairs as well as how well it operates its assets and liabilities.
Eisai Co has accumulated 94.89
B in total debt with debt to equity ratio
(D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. Eisai has a current ratio of 2.02, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Eisai until it has trouble settling it off, either with new capital or with free cash flow. So, Eisai's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eisai sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eisai to invest in growth at high rates of return. When we think about Eisai's use of debt, we should always consider it together with cash and equity.
It offers Aricept for the treatment of alzheimers diseasedementia with Lewy bodies Methycobal for the treatment of peripheral neuropathy and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. Eisai operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11322 people. Eisai Co [ESALF] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Eisai Leadership Team
Elected by the shareholders, the Eisai's board of directors comprises two types of representatives: Eisai inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eisai. The board's role is to monitor Eisai's management team and ensure that shareholders' interests are well served. Eisai's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eisai's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yanhui Feng, Executive Officer, General Manager of Subsidiaries | |
| Kenta Takahashi, Sr. VP, Executive Director of Legal Department and General Counsel of Intellectual Property | |
| Gary Hendler, Sr. VP, CEO of Eisai Europe Ltd and President of Eisai Europe Ltd and President of EMEA Region and President of Eisai Global Oncology Bus. Unit | |
| Haruo Naito, CEO, Representative Corporate Officer and Director | |
| Tatsuyuki Yasuno, Executive Officer, Director of Corporate Planning & Strategy | |
| Nadeem Sarwar, President | |
| Yosuke Akita, Chief VP | |
| Teruyuki Masaka, VP Officer | |
| Sayoko Sasaki, Executive Officer, Director of PR, Manager of Global Access Strategies Office | |
| MD FAAN, VP Health | |
Eisai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eisai a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Eisai Pink Sheet
Eisai financial ratios help investors to determine whether Eisai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eisai with respect to the benefits of owning Eisai security.